Novel oxaborole, nitroimidazole, and aminopyrazoles with activity against experimental cutaneous leishmaniasis

by Van Bocxlaer K, Caridha D, Black C, Vesely B, Leed S, Sciotti RJ, Wijnant GJ, Yardley V, Braillard S, Mowbray CE, Ioset JR, Croft SL. International Journal for Parasitology: Drugs and Drug Resistance 2019, doi: 10.1016/j.ijpddr.2019.02.002

Summary: Three chemical lead series, the nitroimidazoles, benzoxaboroles, and aminopyrazoles have been identified as innovative treatments for visceral leishmaniasis. This study evaluated the anti-leishmanial efficacy of the lead compounds of each of these three chemical classes in in vitro and in vivo models of cutaneous leishmaniasis (CL). DNDI-VL-0690 (nitroimidazole), DNDI-1047 (aminopyrazole), and DNDI-6148 (benzoxaborole) showed excellent antileishmanial activity across a range of species in vitro and against L. major in mice. These compounds offer novel potential drugs for the treatment of CL.

Click here to read the article / PDF